Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature

J Med Case Rep. 2020 Jul 2;14(1):86. doi: 10.1186/s13256-020-02420-x.

Abstract

Background: Due to its rarity, little is known about the clinical presentations and responses to systemic chemotherapies in advanced and/or metastatic cases of paratesticular liposarcoma.

Case presentation: Here, we report the case of a 75-year-old Japanese man with giant paratesticular liposarcoma. Imaging studies revealed a 26 cm tumor in his right scrotum and lung metastases at presentation. He underwent radical orchiectomy followed by systemic chemotherapies. Pathological findings of the resected primary tumor confirmed a dedifferentiated liposarcoma. He then started chemotherapy treatment with gemcitabine plus docetaxel. His disease status was stable for 1 year. Eribulin was used for second-line chemotherapy. He had a relapse at 5 months after eliburin and died at 22 months after diagnosis.

Conclusion: Early diagnosis and curative radical surgery are important for treatment of paratesticular liposarcoma. However, a giant paratesticular liposarcoma could cause metastases, and systemic chemotherapy may be helpful for prolonging survival in patients with metastatic paratesticular liposarcoma.

Keywords: Chemotherapy; Paratesticular liposarcoma; Pulmonary metastasis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use
  • Deoxycytidine / analogs & derivatives
  • Docetaxel / therapeutic use
  • Fatal Outcome
  • Gemcitabine
  • Humans
  • Liposarcoma / diagnostic imaging
  • Liposarcoma / pathology*
  • Liposarcoma / therapy
  • Lung Neoplasms / diagnostic imaging
  • Lung Neoplasms / pathology
  • Lung Neoplasms / secondary*
  • Lung Neoplasms / therapy*
  • Male
  • Orchiectomy
  • Testicular Neoplasms / diagnostic imaging
  • Testicular Neoplasms / pathology*
  • Testicular Neoplasms / therapy

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Docetaxel
  • Gemcitabine